Medplus Health Services Limited announced its un-audited financial results for the quarter ended December 31, 2025. The company reported a revenue of ₹18,061 million (₹1,806.1 crore), marking a 15.7% year-on-year increase from ₹15,614 million in Q3 FY2025 and a 7.5% increase from ₹16,793 million in Q2 FY2026. Gross Margin stood at ₹4,724 million, representing a 26.2% Gross Margin percentage, an increase of 110 basis points year-on-year. Pharmacy Operating EBITDA was ₹925 million, with a 5.2% operating EBITDA margin. Company Operating EBITDA reached ₹968 million, and Operating Cash Flow was ₹905 million, which is 93.5% of Operating EBITDA. The company added 182 stores in the quarter (228 gross additions), bringing the total store count to 5,112 as of December 31, 2025. Stores older than 12 months showed a 10.5% revenue growth year-on-year, with a 12.4% Store Level EBITDA margin and 77.7% Store Level Operating ROCE. The investor presentation also highlighted the company's cluster-based expansion strategy and its omni-channel capabilities, emphasizing a strong network of stores enabling efficient delivery and lower customer acquisition costs. The private label segment continues to grow, with over 1,500 SKUs contributing to higher margins and wallet share. The earnings call to discuss these results was scheduled for Monday, February 02, 2026, at 16:00 Hrs (IST).